drugset / Trial / NCT04267549
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, phase II study aiming to evaluate the feasibility and efficacy of sintilimab (PD-1 inhibitor) in combination of apatinib and two-drug chemotherapy (S-1 plus nab-paclitaxel) as conversion therapy in patients with stage IV gastric cancer in China.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2022-12-01
- Completion
- 2023-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | — |
| Subject | S-1 | Small molecule | 60 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |